{"id":"havrix","rwe":[{"pmid":"41331784","year":"2025","title":"Comparison of safety and immunogenicity between Healive®, Havrix® and live attenuated Hepatitis A vaccines in pediatric population: a systematic review with meta-analysis.","finding":"","journal":"Italian journal of pediatrics","studyType":"Clinical Study"},{"pmid":"39204032","year":"2024","title":"The Immunological and Epidemiological Effectiveness of Pediatric Single-Dose Vaccination against Hepatitis A 9 to 11 Years after Its Implementation in the Tyva Republic, the Russian Federation.","finding":"","journal":"Vaccines","studyType":"Clinical Study"},{"pmid":"29999991","year":"2006","title":"Hepatitis A Vaccine.","finding":"","journal":"","studyType":"Clinical Study"},{"pmid":"37661535","year":"2023","title":"Immunogenicity and safety of Havisure(TM) vaccine developed by Human Biologicals Institute in healthy subjects of 12 months to 49 years of age: A phase II/III, randomized, single blind, non-inferiority study.","finding":"","journal":"Vaccine","studyType":"Clinical Study"},{"pmid":"37470725","year":"2023","title":"Durability of serologic responses to inactivated hepatitis A virus vaccination among people living with HIV following acute hepatitis A outbreak: a 5-year follow-up study.","finding":"","journal":"Emerging microbes & infections","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"GlaxoSmithKline","category":"company"}],"phase":"marketed","safety":{"commonSideEffects":[{"effect":"Injection-site soreness","drugRate":"56%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"14%","severity":"common","organSystem":""},{"effect":"Fatigue","drugRate":"","severity":"common","organSystem":""},{"effect":"Fever >99.5°F (37.5°C)","drugRate":"","severity":"common","organSystem":""},{"effect":"Induration, redness, and swelling of injection site","drugRate":"","severity":"common","organSystem":""},{"effect":"Malaise","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Anorexia","drugRate":"","severity":"common","organSystem":""}],"seriousAdverseEvents":[{"effect":"Injection-site soreness (severe)","drugRate":"0.5%","severity":"serious"}]},"trials":[],"aliases":["INFANRIX","BOOSTRIX","Havrix™","GSK Biologicals' hepatitis A vaccine","inactivated"],"company":"GlaxoSmithKline","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=HAVRIX","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:02:49.078913+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Havrix","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T02:02:56.189839+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:02:54.573536+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HAVRIX","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:02:55.389101+00:00"}},"allNames":["havrix"],"offLabel":[],"synonyms":[],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Havrix is a subunit vaccine that contains a recombinant hepatitis B surface antigen, which is a small protein that elicits an immune response without causing the disease."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Hepatitis_A_vaccine","title":"Hepatitis A vaccine","extract":"Hepatitis A vaccine is a vaccine that prevents hepatitis A. It is effective in around 95% of cases and lasts for at least twenty years and possibly a person's entire life. If given, two doses are recommended beginning after the age of one. It is given by injection into a muscle. The first hepatitis A vaccine was approved in the European Union in 1991, and the United States in 1995. It is on the World Health Organization's List of Essential Medicines."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=havrix","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=havrix","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://en.wikipedia.org/wiki/Hepatitis_A_vaccine","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-31T10:20:56.656282","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:02:57.384917+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"havrix","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06824194","phase":"PHASE3","title":"Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-02-18","conditions":["Pneumococcal Immunization"],"enrollment":2320,"completionDate":"2027-05-12"},{"nctId":"NCT07348692","phase":"PHASE3","title":"Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-20","conditions":["Pneumococcal Immunization","Healthy Volunteers"],"enrollment":896,"completionDate":"2028-01-19"},{"nctId":"NCT06824181","phase":"PHASE3","title":"Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-02-27","conditions":["Pneumococcal Immunization"],"enrollment":580,"completionDate":"2027-09-10"},{"nctId":"NCT05543642","phase":"PHASE4","title":"The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2022-10-11","conditions":["Rheumatic Diseases"],"enrollment":129,"completionDate":"2026-08"},{"nctId":"NCT03859687","phase":"PHASE1","title":"Trial of Antibody Responses by Vitamin Supplementation","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-08-19","conditions":["Healthy Participants"],"enrollment":22,"completionDate":"2025-07-10"},{"nctId":"NCT03654677","phase":"PHASE3","title":"To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine (VITHA-A)","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2017-09-19","conditions":["Hepatitis A Vaccine"],"enrollment":253,"completionDate":"2019-01-31"},{"nctId":"NCT06298708","phase":"PHASE3","title":"Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents","status":"COMPLETED","sponsor":"Chiang Mai University","startDate":"2024-04-27","conditions":["HAV","Hepatitis A","Hep A","Vaccine-Preventable Diseases"],"enrollment":120,"completionDate":"2024-12-09"},{"nctId":"NCT05084508","phase":"PHASE2","title":"A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-02-03","conditions":["Chickenpox"],"enrollment":800,"completionDate":"2024-06-13"},{"nctId":"NCT03917654","phase":"PHASE2","title":"Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-24","conditions":["Malaria"],"enrollment":1301,"completionDate":"2022-10-31"},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":["Healthy Volunteers (Meningococcal Infection)"],"enrollment":2627,"completionDate":"2023-09-22"},{"nctId":"NCT00139113","phase":"PHASE4","title":"Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"1996-09","conditions":["Hepatitis A"],"enrollment":248,"completionDate":"2001-06"},{"nctId":"NCT06277882","phase":"PHASE4","title":"Efficacy and Durability of Hepatitis A Vaccination in Patients With Advanced Fibrosis and Cirrhosis","status":"RECRUITING","sponsor":"Mahidol University","startDate":"2024-02-29","conditions":["Cirrhosis","Hep A","Vaccination"],"enrollment":50,"completionDate":"2025-05-31"},{"nctId":"NCT03654664","phase":"PHASE3","title":"To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2017-06-20","conditions":["Hepatitis A Vaccine"],"enrollment":119,"completionDate":"2019-06-24"},{"nctId":"NCT05012787","phase":"PHASE3","title":"Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases","status":"TERMINATED","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2021-11-12","conditions":["COVID-19"],"enrollment":1,"completionDate":"2022-05-04"},{"nctId":"NCT05613127","phase":"PHASE3","title":"To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24mons-15yrs","status":"UNKNOWN","sponsor":"Boryung Biopharma Co., Ltd.","startDate":"2022-12","conditions":["Hepatitis A","Hep A"],"enrollment":106,"completionDate":"2024-11"},{"nctId":"NCT00880893","phase":"PHASE2","title":"Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-04-07","conditions":["Dengue Fever","Dengue Hemorrhagic Fever","Dengue Virus","Dengue Diseases"],"enrollment":1198,"completionDate":"2014-10-14"},{"nctId":"NCT02747407","phase":"","title":"Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2016-05","conditions":["Astrocytoma","Glioma","Oligodendroglioma"],"enrollment":55,"completionDate":"2021-09-09"},{"nctId":"NCT01041573","phase":"PHASE3","title":"Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-03","conditions":["Encephalitis"],"enrollment":1869,"completionDate":"2011-07"},{"nctId":"NCT01311024","phase":"","title":"Indirect Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage","status":"COMPLETED","sponsor":"Arto Palmu","startDate":"2011-04","conditions":["Pneumococcal Infections"],"enrollment":2341,"completionDate":"2017-12"},{"nctId":"NCT00624819","phase":"PHASE3","title":"Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-03-03","conditions":["Infections, Streptococcal","Streptococcus Pneumoniae Vaccines"],"enrollment":524,"completionDate":"2008-06-02"},{"nctId":"NCT01681992","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-10","conditions":["Measles","Mumps","Rubella","Measles-Mumps-Rubella Vaccine"],"enrollment":4538,"completionDate":"2015-08-18"},{"nctId":"NCT02184572","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-25","conditions":["Measles; Mumps; Rubella","Measles-Mumps-Rubella Vaccine"],"enrollment":1742,"completionDate":"2015-12-22"},{"nctId":"NCT00861380","phase":"PHASE3","title":"Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05-04","conditions":["Infections, Streptococcal","Streptococcus Pneumoniae"],"enrollment":41188,"completionDate":"2013-10-05"},{"nctId":"NCT00839254","phase":"PHASE3","title":"Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02-18","conditions":["Infections, Streptococcal","Streptococcus Pneumoniae"],"enrollment":6181,"completionDate":"2012-01-31"},{"nctId":"NCT00861744","phase":"PHASE2","title":"Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-03","conditions":["Rubella","Mumps","Measles","Measles-Mumps-Rubella Vaccine"],"enrollment":1259,"completionDate":"2012-06-18"},{"nctId":"NCT01702428","phase":"PHASE3","title":"Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-11-09","conditions":["Rubella","Measles","Mumps"],"enrollment":5016,"completionDate":"2015-04-16"},{"nctId":"NCT02712359","phase":"NA","title":"This Study Will Evaluate the Persistence of Hepatitis A Antibodies, 8 Years and 10 Years Later, in Children Who Had Received Havrix at Selected Health Centres of Panama","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-06-01","conditions":["Hepatitis A Vaccine"],"enrollment":1201,"completionDate":"2018-08-22"},{"nctId":"NCT00289731","phase":"PHASE4","title":"Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-11-24","conditions":["Hepatitis B","Hepatitis A"],"enrollment":596,"completionDate":"2004-12-21"},{"nctId":"NCT00937950","phase":"PHASE3","title":"Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-08-05","conditions":["Infections, Papillomavirus"],"enrollment":2022,"completionDate":"2014-01-20"},{"nctId":"NCT00534885","phase":"PHASE4","title":"Safety, Immunogenicity, and Immune Persistence Study of an Inactivated Hepatitis A Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2006-03","conditions":["Hepatitis A"],"enrollment":400,"completionDate":"2017-10"},{"nctId":"NCT00466947","phase":"PHASE3","title":"COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-28","conditions":["Infections, Streptococcal"],"enrollment":23802,"completionDate":"2011-07-28"},{"nctId":"NCT02212457","phase":"PHASE2","title":"Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-21","conditions":["Infections, Meningococcal"],"enrollment":1063,"completionDate":"2016-03-03"},{"nctId":"NCT01282216","phase":"PHASE2","title":"Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2011-04","conditions":["Transplant-Related Cancer"],"enrollment":120,"completionDate":"2016-01"},{"nctId":"NCT01307436","phase":"PHASE3","title":"Long Term Follow-up of a Study to Assess the Safety and Immunogenicity of a Hepatitis A Vaccine Administered With and in the Absence of DTPaHibIPV, OPV and MMR Vaccines","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2007-03-14","conditions":["Hepatitis A"],"enrollment":327,"completionDate":"2013-07-08"},{"nctId":"NCT00128661","phase":"PHASE3","title":"Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-06-30","conditions":["Cervical Cancer","Precancerous Condition"],"enrollment":7466,"completionDate":"2010-12-31"},{"nctId":"NCT01037114","phase":"PHASE4","title":"Long-term Persistence Study in Healthy Adults Previously Vaccinated With Twinrix Adult","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-01-27","conditions":["Hepatitis A","Hepatitis B"],"enrollment":50,"completionDate":"2014-02-28"},{"nctId":"NCT02583412","phase":"PHASE4","title":"Pilot Study of the Immunogenicity, Reactogenicity and Tolerability of Two Schedules of a 4CmenB Vaccine in Adolescents and Young Adults","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2015-09","conditions":["Meningococcal Serogroup B"],"enrollment":120,"completionDate":"2017-06-30"},{"nctId":"NCT00224484","phase":"PHASE3","title":"Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-04-07","conditions":["Herpes Simplex"],"enrollment":5960,"completionDate":"2007-07-24"},{"nctId":"NCT00513409","phase":"PHASE2","title":"Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08-22","conditions":["Infections, Streptococcal"],"enrollment":163,"completionDate":"2008-08-28"},{"nctId":"NCT00578175","phase":"PHASE2","title":"Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-11-20","conditions":["Varicella","Rubella","Mumps","Measles"],"enrollment":1851,"completionDate":"2009-03-17"},{"nctId":"NCT01439360","phase":"PHASE3","title":"An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-10-01","conditions":["Influenza"],"enrollment":12046,"completionDate":"2014-12-31"},{"nctId":"NCT01196026","phase":"PHASE4","title":"Immunogenicity and Safety Study of Fluarix™ Vaccine in Children Who Have Previously Been Vaccinated With Pandemrix™","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09-15","conditions":["Influenza"],"enrollment":162,"completionDate":"2011-05-26"},{"nctId":"NCT01978093","phase":"PHASE3","title":"Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-01","conditions":["Neisseria Meningitidis","Haemophilus Influenzae Type b"],"enrollment":600,"completionDate":"2016-03-18"},{"nctId":"NCT01379937","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-07-28","conditions":["Influenza"],"enrollment":520,"completionDate":"2012-10-05"},{"nctId":"NCT01190215","phase":"PHASE4","title":"Immunogenicity and Safety Study of FluarixTM Vaccine in Children Who Have Previously Been Vaccinated With PandemrixTM","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10-04","conditions":["Influenza"],"enrollment":77,"completionDate":"2011-07-07"},{"nctId":"NCT01000324","phase":"PHASE4","title":"Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated With Twinrix Adult","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-06","conditions":["Hepatitis A","Hepatitis B"],"enrollment":44,"completionDate":"2014-07-25"},{"nctId":"NCT00057330","phase":"PHASE3","title":"HerpeVac Trial for Young Women","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-01-14","conditions":["Herpes Simplex Infection"],"enrollment":8323,"completionDate":"2009-08-22"},{"nctId":"NCT00122681","phase":"PHASE3","title":"Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-05-06","conditions":["Infections, Papillomavirus"],"enrollment":18729,"completionDate":"2009-11-26"},{"nctId":"NCT00197236","phase":"PHASE3","title":"Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-11-11","conditions":["Hepatitis A"],"enrollment":468,"completionDate":"2007-12-03"},{"nctId":"NCT00684671","phase":"PHASE4","title":"Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-05-26","conditions":["Hepatitis A","Hepatitis B"],"enrollment":506,"completionDate":"2008-11-03"},{"nctId":"NCT00197002","phase":"PHASE3","title":"Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-09-11","conditions":["Hepatitis A"],"enrollment":521,"completionDate":"2006-01-16"},{"nctId":"NCT01218308","phase":"PHASE3","title":"A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12-09","conditions":["Influenza"],"enrollment":5220,"completionDate":"2012-01-09"},{"nctId":"NCT00197015","phase":"PHASE3","title":"Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-10-06","conditions":["Hepatitis A"],"enrollment":1474,"completionDate":"2009-06-09"},{"nctId":"NCT00289757","phase":"PHASE4","title":"Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine, Injected According to 0, 6-month Schedule","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-01-01","conditions":["Hepatitis A"],"enrollment":78,"completionDate":"2013-03-01"},{"nctId":"NCT03183492","phase":"PHASE4","title":"Immunogenicity and Persistence of GlaxoSmithKline (GSK) Biologicals' Havrix® in Healthy Adult Subjects Vaccinated at Infancy Under the Hepatitis A Universal Mass Vaccination (UMV) Program in Israel","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2018-05-07","conditions":["Hepatitis A"],"enrollment":0,"completionDate":"2019-01-28"},{"nctId":"NCT00291876","phase":"PHASE4","title":"Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-01-01","conditions":["Hepatitis A"],"enrollment":135,"completionDate":"2013-03-01"},{"nctId":"NCT02038907","phase":"PHASE2","title":"Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-03-28","conditions":["Healthy Volunteers","Norovirus, Prevention"],"enrollment":420,"completionDate":"2015-06-19"},{"nctId":"NCT00603252","phase":"PHASE4","title":"Study to Show That the Combined Hepatitis A and B Vaccine is Non-inferior to Monovalent Vaccines in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-01","conditions":["Hepatitis B","Hepatitis A"],"enrollment":213,"completionDate":"2008-06"},{"nctId":"NCT02526550","phase":"PHASE4","title":"Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX","status":"COMPLETED","sponsor":"Siriraj Hospital","startDate":"2014-06","conditions":["Encephalitis"],"enrollment":50,"completionDate":"2014-07"},{"nctId":"NCT00197249","phase":"PHASE3","title":"Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix or Havrix+Typherix or Tiphim Vi, to Compare Reactogenicity & Immunogenicity","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-05","conditions":["Hepatitis A"],"enrollment":1034,"completionDate":"2005-11"},{"nctId":"NCT00544271","phase":"PHASE4","title":"Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines.","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2003-05","conditions":["Acellular Pertussis","Tetanus","Diphtheria"],"enrollment":720,"completionDate":"2004-01"},{"nctId":"NCT01830855","phase":"PHASE3","title":"A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-04","conditions":["Meningococcal Vaccine"],"enrollment":3596,"completionDate":"2015-04"},{"nctId":"NCT01947465","phase":"","title":"Immunogenicity and Safety of Vaccinations in Immunocompromised Persons","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2013-10","conditions":["Arthritis, Rheumatoid","Spondylarthritis","Vasculitis"],"enrollment":645,"completionDate":"2016-02"},{"nctId":"NCT01360970","phase":"PHASE2","title":"Hepatitis A Vaccine in Patients With Immunomodulating Drugs","status":"COMPLETED","sponsor":"Lars Rombo","startDate":"2009-09","conditions":["Response to Hepatitis A Vaccine"],"enrollment":68,"completionDate":"2011-05"},{"nctId":"NCT02124785","phase":"PHASE4","title":"Evaluation of the Long-term Persistence of Hepatitis A Antibodies in Healthy Adults Who Were Vaccinated 21-25 Years Earlier With GlaxoSmithKline (GSK) Biologicals' Hepatitis A Vaccine, Havrix®","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2015-05","conditions":["Hepatitis A"],"enrollment":0,"completionDate":"2019-07"},{"nctId":"NCT02082639","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2015-02","conditions":["Infections, Papillomavirus"],"enrollment":0,"completionDate":"2015-11"},{"nctId":"NCT01352793","phase":"PHASE3","title":"A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-11","conditions":["Meningitis, Meningococcal"],"enrollment":5715,"completionDate":"2014-09"},{"nctId":"NCT01405677","phase":"PHASE2","title":"Safety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A Vaccine","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2004-06","conditions":["Hepatitis A"],"enrollment":308,"completionDate":"2012-04"},{"nctId":"NCT00596271","phase":"PHASE3","title":"Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2005-09","conditions":["Japanese Encephalitis"],"enrollment":192,"completionDate":"2008-08"},{"nctId":"NCT00474526","phase":"PHASE3","title":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-03","conditions":["Meningitis, Meningococcal"],"enrollment":4545,"completionDate":"2009-11"},{"nctId":"NCT00483470","phase":"PHASE3","title":"Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster Dose","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-06","conditions":["Hepatitis A"],"enrollment":720,"completionDate":"2008-08"},{"nctId":"NCT01349829","phase":"PHASE4","title":"A Study to Evaluate the Safety and Immunogenicity of the Hepatitis A Virus Vaccine HAVpur in Healthy Young Children","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2010-03","conditions":["Hepatitis A"],"enrollment":251,"completionDate":"2011-04"},{"nctId":"NCT01252680","phase":"PHASE4","title":"Immunogenicity and Interchangeability of Two Inactivated Hepatitis A Vaccines","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2010-04","conditions":["Hepatitis A"],"enrollment":303,"completionDate":"2011-05"},{"nctId":"NCT01102296","phase":"NA","title":"Effectiveness of Hepatitis A Virus Vaccination Among Homosexual Males at Risk for Hepatitis A Infection","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2009-06","conditions":["Hepatitis"],"enrollment":582,"completionDate":"2012-04"},{"nctId":"NCT00316706","phase":"PHASE3","title":"Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-10","conditions":["Cervical Intraepithelial Neoplasia","Papillomavirus Infection"],"enrollment":1245,"completionDate":"2009-01"},{"nctId":"NCT00190242","phase":"PHASE3","title":"Immunogenicity and Tolerance of Two Strategies of Anti-HAV Vaccination in HIV-infected Patients","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2003-06","conditions":["HIV Infection"],"enrollment":99,"completionDate":"2009-10"},{"nctId":"NCT00125047","phase":"PHASE4","title":"Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2001-10","conditions":["Typhoid","Paratyphoid Fever"],"enrollment":27231,"completionDate":"2007-08"},{"nctId":"NCT00125008","phase":"PHASE4","title":"Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2003-05","conditions":["Typhoid","Paratyphoid Fever"],"enrollment":37673,"completionDate":"2008-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"GlaxoSmithKline","relationship":"Original Developer"}],"publicationCount":147,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"originalDeveloper":"GlaxoSmithKline","recentPublications":[{"date":"2025 Dec 2","pmid":"41331784","title":"Comparison of safety and immunogenicity between Healive®, Havrix® and live attenuated Hepatitis A vaccines in pediatric population: a systematic review with meta-analysis.","journal":"Italian journal of pediatrics"},{"date":"2024 Aug 10","pmid":"39204032","title":"The Immunological and Epidemiological Effectiveness of Pediatric Single-Dose Vaccination against Hepatitis A 9 to 11 Years after Its Implementation in the Tyva Republic, the Russian Federation.","journal":"Vaccines"},{"date":"2006","pmid":"29999991","title":"Hepatitis A Vaccine.","journal":""},{"date":"2023 Oct 6","pmid":"37661535","title":"Immunogenicity and safety of Havisure(TM) vaccine developed by Human Biologicals Institute in healthy subjects of 12 months to 49 years of age: A phase II/III, randomized, single blind, non-inferiority study.","journal":"Vaccine"},{"date":"2023 Dec","pmid":"37470725","title":"Durability of serologic responses to inactivated hepatitis A virus vaccination among people living with HIV following acute hepatitis A outbreak: a 5-year follow-up study.","journal":"Emerging microbes & infections"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"HAVRIX","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":13,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:02:57.384917+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":true,"trials":true,"score":2}}